Taxceph 250 mg injection is administered intravenously (IV) or intramuscularly (IM) after reconstitution with appropriate diluent (e.g., sterile water for injection, lidocaine for IM). IV administration should be given slowly over 30 minutes. IM injections should be given deep into a large muscle mass.

Ceftriaxone is a bactericidal antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.

• •Hypersensitivity to ceftriaxone, other cephalosporins, or any component of the formulation.
• •History of severe hypersensitivity reaction to any other type of beta-lactam antibacterial agent (e.g., penicillins, carbapenems).
• •Neonates with hyperbilirubinemia, especially premature neonates.
• •Neonates (≤ 28 days of age) receiving intravenous calcium-containing solutions due to risk of precipitation.

Store the powder below 30°C in a dry place, protected from light. Reconstituted solution should be used immediately or stored for a limited time (e.g., 6 hours at room temperature, 24 hours in refrigerator) as per manufacturer guidelines.

In case of overdose, symptoms may include nausea, vomiting, diarrhea, and injection site reactions. Treatment is supportive and symptomatic. Ceftriaxone is not significantly removed by hemodialysis or peritoneal dialysis.

Pregnancy Category B. Studies in animals have not shown harm to the fetus, but there are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed. Ceftriaxone is excreted in low concentrations in human breast milk; use with caution in nursing mothers.